Covance Announces the Acquisition of Signet Laboratories
News Jun 14, 2006
Signet was created in 1989 as a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc.
The Company was founded to continue the mission originally established at CRL - the early detection and recurrence monitoring of patients with cancer and infectious disease.
Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE